skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

Review

(2114) Views  (682) Full article downloads

Authors: Kitty Poon, Allen B King

Published Date October 2010 Volume 2010:2 Pages 213 - 223
DOI: http://dx.doi.org/10.2147/DHPS.S7301

Kitty Poon, Allen B King
Diabetes Care Center, Salinas, CA, USA

Abstract: Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles. Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review summarizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical and observational studies to elucidate the role of each basal insulin analog in therapy.

Keywords: glargine, detemir, safety, hypoglycemia, weight, glucose variability






Readers of this article also read:

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
Editorial
Zinc oxide nanoparticles as selective killers of proliferating cells
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio